While targeted therapies have nearly doubled survival for some cancers, lung cancer continues to claim more lives than any ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT ...

Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development and improved survival in mice, demonstrating the potential of intercepting ...

Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study published in the ...

A newly released publication examines how deuterium concentration may influence gene activity in lung cancer cells. The study explores how shifts in this ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...